文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Organoid Cultures Derived from Patients with Advanced Prostate Cancer
侵权投诉

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

A

PTEN expression

TP53 expression

C

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

D

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Figure5.LossofTumorSuppressorsPTEN,TP53,RB1,andCDKN2AinProstateOrganoidLines

(A)OncoprintviewofPTEN,TP53,RB1,andCDKN2A.The lloftherectangledenotescopynumberchange(homozygousdeletiondarkblue,heterozygousdeletionlightblue,GAIN:red).Theborderoftherectangledenotesgeneexpres-sionchange.Greensquaredenotesmutation.(B)WesternblotofPTEN,RB,phosphorylatedRB(S807/S811),p16,andGAPDHofnormalprostateorganoidsandprostatecancerorganoidlines.(C–E)GeneexpressionofPTEN,TP53,andRB1innormalprostatetissue,primarycancer,andCRPCfromtheMichigandataset.ForCRPC,copynumberandmutationaldataareavailableformostsamples.Opencirclesindicatesthatmutational/copynumberdataarenotavailable.Green llin-dicatesmutation.Lightanddarkblue llindicatesheterozygousandhomozygousloss.

(F)ScatterplotofgeneexpressionofRB1andCDKN2Ainbenign(orangetriangle),primarycancer(pinksquare),andCRPC(blackcircles).SeealsoFigureS5forRNA-seqandArray-CGHtracksofCDKN2A.

RB1 expression

B

RB1 expression

E

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

F

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

CDKN2A expression

PriorstudieshavedocumentedheterozygouslossRB1inprostatecancer,suggestinghaploinsuf ciencyissuf cienttopromotetumorigenesis(Sharmaetal.,2010).Ofnote,threeor-ganoidlineshadheterozygousRB1loss(MSK-PCa1,MSK-PCa4,andMSK-PCa5)buthadnodetectableRB1transcriptorRBproteinexpression(Figures5Aand5B).RNA-seqanalysisrevealedcompleteRB1deletioninMSK-PCa5thatwasmissedonarray-CGHandWES(FigureS1C),possiblyexplainedbycopy-neutralgenomicrearrangementoftheremainingallele.ToexplorewhethercompletelossofRB1maybemorecommoninprostatecancerthanpreviouslyappreciated,weexaminedtheRB1genelocusandmRNAlevelsinaclinicalCRPCdataset(Grassoetal.,2012)andfoundhomozygouslossandreducedexpressionin 70%ofcases(Figure5E).Interestingly,twolineswithoutRB1alterations(MSK-PCa3andMSK-PCa6)havebial-leliclossofthetumorsuppressorlocusCDKN2A(FiguresS5AandS5B),providinganothermechanismtodisableRBpathwayfunction.ConsistentwithCDKN2Ageneloss,thesetwolineshavehyperphosphorylatedRBasaconsequenceofunre-strainedCDK4/6kinaseactivityduetolossofp16.CDKN2AdeletionisseenrarelyinclinicalCRPCsamplesamongtheRBintactsubset(3/67totalsamples,4.5%).Rather,mostCRPCtumorsexhibitCDKN2Aoverexpression,likelyduep53/RBloss(Figure5F).Indeed,theorganoidlineswithRBproteinlossandP53mutationhadincreasedp16expression(Figure5B).Patient-DerivedOrganoidLinesasGeneticallyManipulatableModelsforDrugResponse

ToexplorethesuitabilityofCRPC-derivedorganoidlinesfordrugtesting,weperformedgrowthassaystodeterminesensi-tivitytoenzalutamideaswellastotwoPI3-kinasepathwayinhib-itors,everolimusandBKM-120,thatarecurrentlyinclinicaltrialsforCRPC(Figures6A–6C).TheAR-ampli edMSK-PCa2linewasexquisitelysensitivetoenzalutamidewithanIC-50ofapproximately50nM,whereastheotherlineswereresistant.

8Cell159,1–12,September25,2014ª2014ElsevierInc.

TheMSK-PCa2organoidline,whichharborsbothPTENlossandPIK3R1mutation,wassensitivetobotheverolimusandBKM-120.Theseorganoidmodelsarealsoamenabletoinvivostudiesusingbioluminescencetotracktumorresponse.Asexpected,AR-ampli edMSK-PCa2-derivedxenograftswerehighlysensitivetoenzalutamide,recapitulatingtheinvitroresult(Figures6Dand6E),whereasARnegativeMSK-PCa1xeno-graftswereresistant.ForbothMSK-PCa1andMSK-PCa2,ever-olimussigni cantlyslowedtumorgrowthratebutdidnotinduceshrinkage.Furthermore,everolimussigni cantlyincreasedthetumorresponsetoenzalutamideinMSK-PCa2.DISCUSSION

Thepastfewyearshaveseenadramaticincreaseinthenum-berofapprovedtherapies,withseveralpromisinginvestiga-tionalagentsinlatestagedevelopmenttotreatCRPC.Theseincludethenext-generationantiandrogenenzalutamideandtheandrogensynthesisinhibitorabirateroneacetate,bothofwhichhavebeenshowntosigni cantlyprolonglife(deBonoetal.,2011;Ryanetal.,2012;Scheretal.,2012).Theresponse,however,ishighlyvariableandonly 30%attaindurableresponseof>6months(RathkopfandScher,2013).Thus,bothanimprovedunderstandingofthemoleculardeterminantsofresistancetotheseagentsaswellasdevelopmentofnovelther-apeuticsareneeded.Progresshasbeenhamperedbythelackofinvitromodelsthataccuratelyrepresentthespectrumofdisease.Here,wedescribeamethodthatallowsfortheestab-lishmentofpatient-derived3Dorganoidlines.Asthisreportrep-resentsourinitialattempt,weanticipatethemethodcanbefurtheroptimizedtoimprovethesuccessratetogeneratethelargerepositoryoforganoidlinesrequiredtostudythishighlyheterogeneousdisease.Biopsyandcharacterizationofmeta-staticlesionsareincreasinglyincorporatedintotherapeuticclinicaltrialsoftargetedagentsinprostatecancer.Thisclinical

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

上一页第8页

你可能喜欢

热门文档

相关文档

  • Serum peptidome

    from patients with advanced prostate, bladder, or breast cancer as well as...Regardless of whether the peptidome is derived from the tissue/microenvironment...

  • Cryopreservation of mature monocyte-derived human d...

    [6], advanced melanoma [11], prostate cancer [...from healthy donors and from patients with chronic...In DC cultures of four healthy donors, Freezing ...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email